NCT06359821View on ClinicalTrials.gov

Evaluate Safety, Whole-Body Distribution and Radiation Dosimetry in Metastatic Castration Resistant Prostate Cancer

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

May 17, 2024

Primary Completion Date

October 14, 2024

Study Completion Date

October 14, 2024

Conditions
Metastatic Prostate Cancer
Interventions
DRUG

ZA-001

Study drug ZA-001 administered via intravenous injection.

Trial Locations (1)

Unknown

West China Hospital, Chengdu

All Listed Sponsors
lead

Sichuan University

OTHER

NCT06359821 - Evaluate Safety, Whole-Body Distribution and Radiation Dosimetry in Metastatic Castration Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter